View ValuationNanosonics 향후 성장Future 기준 점검 3/6Nanosonics (는) 각각 연간 21.2% 및 8.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 20.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.9% 로 예상됩니다.핵심 정보21.2%이익 성장률20.65%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률8.6%향후 자기자본이익률11.91%애널리스트 커버리지Good마지막 업데이트13 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 27Nanosonics Limited to Report First Half, 2026 Results on Feb 24, 2026Nanosonics Limited announced that they will report first half, 2026 results on Feb 24, 2026공시 • Jan 20Nanosonics Limited Appoints Sarah Butler as Independent Non-Executive Director and Member of Innovation and Development Committee, Effective January 19, 2026Nanosonics Limited has appointed Sarah Butler as an independent non-executive director, effective from January 19, 2026. Sarah Butler brings 35 years of diverse expertise in supporting organizations across regulated sectors to achieve global growth, scale their impact and improve diversity and inclusion. Throughout her career, she has specialised in strategic consulting, serving as a partner at Booz Allen Hamilton, Booz & Company and most recently at PwC, where she led PwC’s AUD 2 billion Global Health practice through the COVID-19 pandemic. At Booz & Company, she held several senior positions, including Global Insurance Leader and Managing Director for Greater China. Sarah Butler currently serves as an independent non-executive director of Australian Clinical Labs, Lumonus, a private healthtech SaaS company, and health research institute The George Institute for Global Health, where she is Chair of the People & REM Committee. She is also a director of Insurance Manufacturers of Australia Pty Limited (IMA), a joint venture between IAG and RACV focused on personal insurance. Previously, Sarah Butler was a director at Booz & Company, where she chaired the Audit & Risk Committee, and at PwC Australia. She is an FAICD and was a scholar at the University of Cambridge, United Kingdom, where she received a Bachelor of Arts (Hons) and a Master of Arts in Natural Sciences (Chemistry). Sarah Butler will serve as a member of Nanosonics’ Innovation and Development Committee.공시 • Nov 07Nanosonics Limited (ASX:NAN) announces an Equity Buyback for AUD 20 million worth of its shares.Nanosonics Limited (ASX:NAN) announces an share repurchase program. Under the program, the company will repurchases up to $20 million worth of its shares. The program will valid till November 4, 2026. As of November 5, 2025, the company had 304,164,829 shares in issue.공시 • Sep 05Nanosonics Limited, Annual General Meeting, Nov 05, 2025Nanosonics Limited, Annual General Meeting, Nov 05, 2025.공시 • Aug 07Nanosonics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Nanosonics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025공시 • Jan 23Nanosonics Limited to Report First Half, 2025 Results on Feb 20, 2025Nanosonics Limited announced that they will report first half, 2025 results on Feb 20, 2025공시 • Jan 14Nanosonics Limited Appoints Gerard Dalbosco as an Independent Non-Executive Director, Effective 14 January 2025Nanosonics Limited announced the appointment of Gerard Dalbosco as an Independent Non-Executive Director of Nanosonics, effective 14 January 2025. Mr. Dalbosco brings extensive experience to the Company. He had a distinguished executive career, most notably at EY, where he held a number of senior leadership roles spanning multiple regions and functions, including Oceania Managing Partner and CEO, Asia Pacific Joint Deputy CEO, and Oceania Managing Partner - Transaction Advisory Services. Prior to these roles, he was instrumental in advising clients across a range of industries, focusing on mergers and acquisitions, financial due diligence, and commercial strategy. Beyond his corporate career, Gerard has broad governance experience. He is currently a Director at Medibank Private Ltd. and serves as Chair of Melbourne Archdiocese Catholic Schools. He is also Chair of the Gillespie Family Council & Gillespie Family Foundation (founders/owners of Bakers Delight). Previous governance roles include Mercy Health & Aged Care (Director and Chair of Finance and Audit Committee), Berry Street Victoria (Director and Member of Finance Committee) and the Committee for Melbourne (Director, Deputy Chair and Chair of Finance, Audit and Risk). Gerard is a Fellow of the Institute of Chartered Accountants in Australia, a Graduate of the Australian Institute of Company Directors and holds a Bachelor of Commerce and Masters in Applied Finance from Melbourne University. Gerard will be a member of both the Audit & Risk Committee and the People, Safety, and Remuneration Committee. It is expected that Mr. Dalbosco will assume the role of Chairman of the Audit & Risk Committee following the release of the first half of fiscal year 2025 accounts.공시 • Oct 18Nanosonics Limited Announces Board RetirementsNanosonics Limited provided an update in respect of its Board renewal process. The Company confirms that David Fisher has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Dr. Fisher has been a member of the Board since July 2001 and has made a longstanding and significant contribution to the Company during his tenure including as Chair of the Innovation & Development Committee for many years, and interim CEO for a period. The Company also confirmed that Geoff Wilson has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Mr. Wilson has made a significant contribution to the Company both as Chair of the Audit & Risk Committee and as a valued Non-Executive Director since joining the Board 5 years ago.공시 • Sep 24Nanosonics Limited, Annual General Meeting, Nov 12, 2024Nanosonics Limited, Annual General Meeting, Nov 12, 2024. Location: at nanosonics head office at level 1, building a,7-11 talavera road, macquarie park nsw 2113, Australia공시 • Jul 15Nanosonics Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Nanosonics Limited announced that they will report fiscal year 2024 results on Aug 27, 2024공시 • Jan 23+ 1 more updateNanosonics Limited to Report First Half, 2024 Results on Feb 26, 2024Nanosonics Limited announced that they will report first half, 2024 results on Feb 26, 2024공시 • Sep 07Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023Nanosonics Limited announced the appointment of Jason Burriss as Chief Financial Officer (CFO), effective 3 October 2023. Jason is an experienced Chief Financial Officer with a 25-year career spanning healthcare, financial services, and construction over four continents. Jason performed senior finance roles with General Electric (GE) for 15 years, notably CFO for GE Healthcare Australia & New Zealand. More recently, Jason held several international CFO roles for the Hilti Group over 6 years. During this time, Jason built the return-on-investment strategy for South Asia Pacific before relocating from Singapore to Dubai to focus on growth with distribution partners across more than 50 countries in the Middle East, Turkey, and Africa. Jason holds a Bachelor of Commerce from the University of Western Sydney, is a member of the Institute of Chartered Accountants Australia and New Zealand and attained executive education in Strategic Financial Analysis from Harvard Business School, USA.공시 • Aug 25Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023Nanosonics Limited announced the appointment of Dr. Larry Marshall as a Non- executive Director of Nanosonics effective 3 October 2023. Dr. Marshall brings significant experience to the Company. Dr. Marshall is a technology innovator, physicist and business leader with over 30 years' experience in leadership of technology companies. He has founded companies and driven innovation in Silicon Valley and Australia. Until July 2023, Dr. Marshall was Chief Executive of CSIRO for 8½ years. Under his stewardship CSIRO doubled the value delivered to stakeholders, achieved a record $1.6 Billion in revenue, enjoyed the first sustained growth in 30 years, and became the first Australian entity to be Thompson Reuters rated in the Global Top 20 Innovation organisations. Dr. Marshall lived in the United States for 26 years, where he co-founded 6 successful companies in a range of markets including medical device. Over the past 30 years he has served as CEO/MD of 6 companies, and Chairman of 4. He was MD, then co-Chairman of Arasor, a developer and manufacturer of integrated optical and wireless solutions, which he took public in 2006. In 2007, Dr. Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specialising in Australian innovation. Dr. Marshall holds a PhD in Physics, and a Bachelor of Science (Hons) from Macquarie University. He is a Fellow of the AICD, ATSE, AIP, and a Federation Fellow. He has been a director of 20 private sector boards in Australia and the United States, including boards of 2 companies that were subsequently listed on the Nasdaq and on the ASX respectively.공시 • Aug 22Nanosonics Limited, Annual General Meeting, Nov 03, 2023Nanosonics Limited, Annual General Meeting, Nov 03, 2023, at 11:00 E. Australia Standard Time. Location: Nanosonics Office Level 1 Building A, 7-11 Talavera Road, Macquarie Park New South Wales Australia공시 • Aug 03Nanosonics Limited to Report Fiscal Year 2023 Results on Aug 22, 2023Nanosonics Limited announced that they will report fiscal year 2023 results on Aug 22, 2023공시 • Jul 21Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023Nanosonics Limited announced the appointment of Dr. Tracey Batten as a Non-executive Director of Nanosonics effective 26 September 2023. Dr. Batten brings to Nanosonics a wealth of experience in the healthcare sector gained in both non-executive and executive roles, as well as medical practitioner and clinical roles, over more than 30 years. During her executive career, Dr. Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles. Dr. Batten holds a Bachelor of Medicine/Bachelor of Surgery from the University of Melbourne, a Master of Health Administration from the University of New South Wales, and an MBA from Harvard Business School. Dr. Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited, the Accident Compensation Corporation and the National Institute of Water and Atmospheric Research. In addition, Dr. Batten was previously non-executive director of Abano Healthcare Group Ltd. and various other healthcare related research institutes, charities and industry and government bodies.공시 • May 12+ 1 more updateNanosonics Announces Company Secretary ChangesNanosonics announced the resignation of Company Secretary, McGregor Grant after 12 years in the role. Mr. Matthew Carbines, General Counsel, and member of the Executive team has been appointed as Company Secretary effectively immediately.공시 • Feb 15Nanosonics Limited to Report First Half, 2023 Results on Feb 23, 2023Nanosonics Limited announced that they will report first half, 2023 results on Feb 23, 2023이익 및 매출 성장 예측OTCPK:NNCS.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202825031273886/30/202723023183086/30/2026211171222812/31/2025207212429N/A9/30/2025203213037N/A6/30/2025199213544N/A3/31/2025191193139N/A12/31/2024184172835N/A9/30/2024177152429N/A6/30/2024170132023N/A3/31/2024167142123N/A12/31/2023164162224N/A9/30/2023165182124N/A6/30/2023166202023N/A3/31/2023154151520N/A12/31/2022141101016N/A9/30/20221317511N/A6/30/2022120407N/A3/31/2022120727N/A12/31/20211211148N/A9/30/20211121058N/A6/30/2021103967N/A3/31/202199779N/A12/31/2020956810N/A9/30/20209781516N/A6/30/2020100102123N/A3/31/202096111618N/A12/31/201992121113N/A9/30/20198813N/A9N/A6/30/20198414N/A5N/A3/31/20197812N/A6N/A12/31/20187111N/A6N/A9/30/2018668N/A8N/A6/30/2018616N/A9N/A3/31/2018616N/A11N/A12/31/2017616N/A13N/A9/30/20176416N/A15N/A6/30/20176826N/A16N/A3/31/20176526N/A16N/A12/31/20166325N/A16N/A9/30/20165313N/A10N/A6/30/2016430N/A3N/A3/31/201633-5N/A-3N/A12/31/201523-10N/A-8N/A9/30/201523-8N/A-5N/A6/30/201522-5N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NNCS.F 의 연간 예상 수익 증가율(21.2%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: NNCS.F 의 연간 수익(21.2%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: NNCS.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: NNCS.F 의 수익(연간 8.6%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: NNCS.F 의 수익(연간 8.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NNCS.F의 자본 수익률은 3년 후 11.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 04:34종가2026/05/15 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nanosonics Limited는 14명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Josh KannourakisBarrenjoey Markets Pty LimitedJohn HesterBell PotterLyanne HarrisonBofA Global Research11명의 분석가 더 보기
공시 • Jan 27Nanosonics Limited to Report First Half, 2026 Results on Feb 24, 2026Nanosonics Limited announced that they will report first half, 2026 results on Feb 24, 2026
공시 • Jan 20Nanosonics Limited Appoints Sarah Butler as Independent Non-Executive Director and Member of Innovation and Development Committee, Effective January 19, 2026Nanosonics Limited has appointed Sarah Butler as an independent non-executive director, effective from January 19, 2026. Sarah Butler brings 35 years of diverse expertise in supporting organizations across regulated sectors to achieve global growth, scale their impact and improve diversity and inclusion. Throughout her career, she has specialised in strategic consulting, serving as a partner at Booz Allen Hamilton, Booz & Company and most recently at PwC, where she led PwC’s AUD 2 billion Global Health practice through the COVID-19 pandemic. At Booz & Company, she held several senior positions, including Global Insurance Leader and Managing Director for Greater China. Sarah Butler currently serves as an independent non-executive director of Australian Clinical Labs, Lumonus, a private healthtech SaaS company, and health research institute The George Institute for Global Health, where she is Chair of the People & REM Committee. She is also a director of Insurance Manufacturers of Australia Pty Limited (IMA), a joint venture between IAG and RACV focused on personal insurance. Previously, Sarah Butler was a director at Booz & Company, where she chaired the Audit & Risk Committee, and at PwC Australia. She is an FAICD and was a scholar at the University of Cambridge, United Kingdom, where she received a Bachelor of Arts (Hons) and a Master of Arts in Natural Sciences (Chemistry). Sarah Butler will serve as a member of Nanosonics’ Innovation and Development Committee.
공시 • Nov 07Nanosonics Limited (ASX:NAN) announces an Equity Buyback for AUD 20 million worth of its shares.Nanosonics Limited (ASX:NAN) announces an share repurchase program. Under the program, the company will repurchases up to $20 million worth of its shares. The program will valid till November 4, 2026. As of November 5, 2025, the company had 304,164,829 shares in issue.
공시 • Sep 05Nanosonics Limited, Annual General Meeting, Nov 05, 2025Nanosonics Limited, Annual General Meeting, Nov 05, 2025.
공시 • Aug 07Nanosonics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025Nanosonics Limited announced that they will report fiscal year 2025 results on Aug 26, 2025
공시 • Jan 23Nanosonics Limited to Report First Half, 2025 Results on Feb 20, 2025Nanosonics Limited announced that they will report first half, 2025 results on Feb 20, 2025
공시 • Jan 14Nanosonics Limited Appoints Gerard Dalbosco as an Independent Non-Executive Director, Effective 14 January 2025Nanosonics Limited announced the appointment of Gerard Dalbosco as an Independent Non-Executive Director of Nanosonics, effective 14 January 2025. Mr. Dalbosco brings extensive experience to the Company. He had a distinguished executive career, most notably at EY, where he held a number of senior leadership roles spanning multiple regions and functions, including Oceania Managing Partner and CEO, Asia Pacific Joint Deputy CEO, and Oceania Managing Partner - Transaction Advisory Services. Prior to these roles, he was instrumental in advising clients across a range of industries, focusing on mergers and acquisitions, financial due diligence, and commercial strategy. Beyond his corporate career, Gerard has broad governance experience. He is currently a Director at Medibank Private Ltd. and serves as Chair of Melbourne Archdiocese Catholic Schools. He is also Chair of the Gillespie Family Council & Gillespie Family Foundation (founders/owners of Bakers Delight). Previous governance roles include Mercy Health & Aged Care (Director and Chair of Finance and Audit Committee), Berry Street Victoria (Director and Member of Finance Committee) and the Committee for Melbourne (Director, Deputy Chair and Chair of Finance, Audit and Risk). Gerard is a Fellow of the Institute of Chartered Accountants in Australia, a Graduate of the Australian Institute of Company Directors and holds a Bachelor of Commerce and Masters in Applied Finance from Melbourne University. Gerard will be a member of both the Audit & Risk Committee and the People, Safety, and Remuneration Committee. It is expected that Mr. Dalbosco will assume the role of Chairman of the Audit & Risk Committee following the release of the first half of fiscal year 2025 accounts.
공시 • Oct 18Nanosonics Limited Announces Board RetirementsNanosonics Limited provided an update in respect of its Board renewal process. The Company confirms that David Fisher has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Dr. Fisher has been a member of the Board since July 2001 and has made a longstanding and significant contribution to the Company during his tenure including as Chair of the Innovation & Development Committee for many years, and interim CEO for a period. The Company also confirmed that Geoff Wilson has indicated that he intends to not seek re-election at this year's AGM on 12 November 2024. Mr. Wilson has made a significant contribution to the Company both as Chair of the Audit & Risk Committee and as a valued Non-Executive Director since joining the Board 5 years ago.
공시 • Sep 24Nanosonics Limited, Annual General Meeting, Nov 12, 2024Nanosonics Limited, Annual General Meeting, Nov 12, 2024. Location: at nanosonics head office at level 1, building a,7-11 talavera road, macquarie park nsw 2113, Australia
공시 • Jul 15Nanosonics Limited to Report Fiscal Year 2024 Results on Aug 27, 2024Nanosonics Limited announced that they will report fiscal year 2024 results on Aug 27, 2024
공시 • Jan 23+ 1 more updateNanosonics Limited to Report First Half, 2024 Results on Feb 26, 2024Nanosonics Limited announced that they will report first half, 2024 results on Feb 26, 2024
공시 • Sep 07Nanosonics Limited Announces Appointment of Jason Burriss as Chief Financial Officer, Effective 3 October 2023Nanosonics Limited announced the appointment of Jason Burriss as Chief Financial Officer (CFO), effective 3 October 2023. Jason is an experienced Chief Financial Officer with a 25-year career spanning healthcare, financial services, and construction over four continents. Jason performed senior finance roles with General Electric (GE) for 15 years, notably CFO for GE Healthcare Australia & New Zealand. More recently, Jason held several international CFO roles for the Hilti Group over 6 years. During this time, Jason built the return-on-investment strategy for South Asia Pacific before relocating from Singapore to Dubai to focus on growth with distribution partners across more than 50 countries in the Middle East, Turkey, and Africa. Jason holds a Bachelor of Commerce from the University of Western Sydney, is a member of the Institute of Chartered Accountants Australia and New Zealand and attained executive education in Strategic Financial Analysis from Harvard Business School, USA.
공시 • Aug 25Nanosonics Limited Appoints Larry Marshall as Non- Executive Director, Effective from 3 October 2023Nanosonics Limited announced the appointment of Dr. Larry Marshall as a Non- executive Director of Nanosonics effective 3 October 2023. Dr. Marshall brings significant experience to the Company. Dr. Marshall is a technology innovator, physicist and business leader with over 30 years' experience in leadership of technology companies. He has founded companies and driven innovation in Silicon Valley and Australia. Until July 2023, Dr. Marshall was Chief Executive of CSIRO for 8½ years. Under his stewardship CSIRO doubled the value delivered to stakeholders, achieved a record $1.6 Billion in revenue, enjoyed the first sustained growth in 30 years, and became the first Australian entity to be Thompson Reuters rated in the Global Top 20 Innovation organisations. Dr. Marshall lived in the United States for 26 years, where he co-founded 6 successful companies in a range of markets including medical device. Over the past 30 years he has served as CEO/MD of 6 companies, and Chairman of 4. He was MD, then co-Chairman of Arasor, a developer and manufacturer of integrated optical and wireless solutions, which he took public in 2006. In 2007, Dr. Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specialising in Australian innovation. Dr. Marshall holds a PhD in Physics, and a Bachelor of Science (Hons) from Macquarie University. He is a Fellow of the AICD, ATSE, AIP, and a Federation Fellow. He has been a director of 20 private sector boards in Australia and the United States, including boards of 2 companies that were subsequently listed on the Nasdaq and on the ASX respectively.
공시 • Aug 22Nanosonics Limited, Annual General Meeting, Nov 03, 2023Nanosonics Limited, Annual General Meeting, Nov 03, 2023, at 11:00 E. Australia Standard Time. Location: Nanosonics Office Level 1 Building A, 7-11 Talavera Road, Macquarie Park New South Wales Australia
공시 • Aug 03Nanosonics Limited to Report Fiscal Year 2023 Results on Aug 22, 2023Nanosonics Limited announced that they will report fiscal year 2023 results on Aug 22, 2023
공시 • Jul 21Nanosonics Limited Announces the Appointment of Tracey Batten as Non-Executive Director, Effective 26 September 2023Nanosonics Limited announced the appointment of Dr. Tracey Batten as a Non-executive Director of Nanosonics effective 26 September 2023. Dr. Batten brings to Nanosonics a wealth of experience in the healthcare sector gained in both non-executive and executive roles, as well as medical practitioner and clinical roles, over more than 30 years. During her executive career, Dr. Batten was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health, CEO of Dental Health Services Victoria and held various other clinical and medical leadership roles. Dr. Batten holds a Bachelor of Medicine/Bachelor of Surgery from the University of Melbourne, a Master of Health Administration from the University of New South Wales, and an MBA from Harvard Business School. Dr. Batten is currently a non-executive director of Medibank Private Ltd, the EBOS Group Limited, the Accident Compensation Corporation and the National Institute of Water and Atmospheric Research. In addition, Dr. Batten was previously non-executive director of Abano Healthcare Group Ltd. and various other healthcare related research institutes, charities and industry and government bodies.
공시 • May 12+ 1 more updateNanosonics Announces Company Secretary ChangesNanosonics announced the resignation of Company Secretary, McGregor Grant after 12 years in the role. Mr. Matthew Carbines, General Counsel, and member of the Executive team has been appointed as Company Secretary effectively immediately.
공시 • Feb 15Nanosonics Limited to Report First Half, 2023 Results on Feb 23, 2023Nanosonics Limited announced that they will report first half, 2023 results on Feb 23, 2023